Omnimmune Holdings Inc. (OMMH)

Overview

Omnimmune Holdings, Inc., operating through its subsidiary Omnimmune Corp., positions itself as a pioneering force in the field of biotechnology, primarily within the United States. This development-stage company is dedicated to the fusion of therapeutic, diagnostic, and prognostic technologies aimed at combating cancer. Based in the robust scientific ecosystem of Houston, Texas, Omnimmune Holdings, Inc. is spearheading innovations with a clear focus on monoclonal antibody technologies. Their strategy encompasses a holistic approach to cancer treatment, aiming to revolutionize how the disease is predicted, diagnosed, and treated.

Products and Services

The core offerings of Omnimmune Holdings, Inc. are designed to cater to various aspects of cancer treatment, focusing on personalized approaches that leverage cutting-edge biotechnological advancements. Below is an intricate look at their main product and service lines:

• Monoclonal Antibody Technologies: Omnimmune owns the rights to several pioneering monoclonal antibody technologies. These therapies offer a form of passive immunization, targeting specific antigens present on cancer cells, thereby enabling the immune system to better identify and destroy these harmful cells.
• Personalized Cancer Treatment: The company is at the forefront of developing personalized cancer treatments. This includes the utilization of prophylactic and therapeutic vaccines aimed at active immunization, alongside their work in passive immunization. These treatments are tailored to the individual's genetic makeup, enhancing the effectiveness and minimizing the side effects of cancer therapies.
• Genomic-based Products: Targeting a specific hormone known as human chorionic gonadotropin, Omnimmune is working on genomic-based products. This innovative approach seeks to harness the power of genomics to create treatments that are more precise and targeted, thus potentially improving outcomes in cancer care.
• Phase I Clinical Trials: With an ongoing commitment to advancing its research and development efforts, Omnimmune plans to initiate a Phase I trial focused on their lead candidate, anti-human chorionic gonadotropin beta subunit monoclonal antibodies. This is based upon promising results from diagnostic trials, underscoring the company's dedication to translating scientific discoveries into tangible treatments.